NeoGenomics Statistics
Total Valuation
NeoGenomics has a market cap or net worth of $1.18 billion. The enterprise value is $1.43 billion.
Important Dates
The next estimated earnings date is Tuesday, April 29, 2025, before market open.
| Earnings Date | Apr 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NeoGenomics has 128.46 million shares outstanding. The number of shares has increased by 0.92% in one year.
| Current Share Class | 128.46M |
| Shares Outstanding | 128.46M |
| Shares Change (YoY) | +0.92% |
| Shares Change (QoQ) | +0.16% |
| Owned by Insiders (%) | 1.20% |
| Owned by Institutions (%) | 94.64% |
| Float | 119.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 58.71 |
| PS Ratio | 1.84 |
| Forward PS | 1.63 |
| PB Ratio | 1.37 |
| P/TBV Ratio | 30.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 172.58 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.17 |
| EV / EBITDA | 1,679.02 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.98, with a Debt / Equity ratio of 0.67.
| Current Ratio | 1.98 |
| Quick Ratio | 1.78 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | 48.11 |
| Debt / FCF | n/a |
| Interest Coverage | -10.83 |
Financial Efficiency
Return on equity (ROE) is -8.54% and return on invested capital (ROIC) is -2.93%.
| Return on Equity (ROE) | -8.54% |
| Return on Assets (ROA) | -2.70% |
| Return on Invested Capital (ROIC) | -2.93% |
| Return on Capital Employed (ROCE) | -5.36% |
| Revenue Per Employee | $300,257 |
| Profits Per Employee | -$35,785 |
| Employee Count | 2,200 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 14.56 |
Taxes
| Income Tax | -1.95M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.71% in the last 52 weeks. The beta is 1.28, so NeoGenomics's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -36.71% |
| 50-Day Moving Average | 11.91 |
| 200-Day Moving Average | 14.54 |
| Relative Strength Index (RSI) | 41.15 |
| Average Volume (20 Days) | 1,521,148 |
Short Selling Information
| Short Interest | 4.22M |
| Short Previous Month | 3.49M |
| Short % of Shares Out | 3.29% |
| Short % of Float | 3.52% |
| Short Ratio (days to cover) | 2.58 |
Income Statement
In the last 12 months, NeoGenomics had revenue of $660.57 million and -$78.73 million in losses. Loss per share was -$0.62.
| Revenue | 660.57M |
| Gross Profit | 290.10M |
| Operating Income | -71.70M |
| Pretax Income | -83.44M |
| Net Income | -78.73M |
| EBITDA | 852,000 |
| EBIT | -71.70M |
| Loss Per Share | -$0.62 |
Full Income StatementBalance Sheet
The company has $386.84 million in cash and $605.33 million in debt, giving a net cash position of -$218.49 million or -$1.70 per share.
| Cash & Cash Equivalents | 386.84M |
| Total Debt | 605.33M |
| Net Cash | -218.49M |
| Net Cash Per Share | -$1.70 |
| Equity (Book Value) | 902.34M |
| Book Value Per Share | 7.04 |
| Working Capital | 294.78M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $7.02 million and capital expenditures -$41.06 million, giving a free cash flow of -$34.04 million.
| Operating Cash Flow | 7.02M |
| Capital Expenditures | -41.06M |
| Free Cash Flow | -34.04M |
| FCF Per Share | -$0.26 |
Full Cash Flow StatementMargins
Gross margin is 43.92%, with operating and profit margins of -10.85% and -11.92%.
| Gross Margin | 43.92% |
| Operating Margin | -10.85% |
| Pretax Margin | -12.21% |
| Profit Margin | -11.92% |
| EBITDA Margin | 0.13% |
| EBIT Margin | -10.85% |
| FCF Margin | n/a |
Dividends & Yields
NeoGenomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.92% |
| Shareholder Yield | -0.92% |
| Earnings Yield | -6.50% |
| FCF Yield | -2.81% |
Dividend DetailsAnalyst Forecast
The average price target for NeoGenomics is $19.78, which is 115.47% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.78 |
| Price Target Difference | 115.47% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on April 16, 2003. It was a reverse split with a ratio of 0.01:1.
| Last Split Date | Apr 16, 2003 |
| Split Type | Reverse |
| Split Ratio | 0.01:1 |
Scores
NeoGenomics has an Altman Z-Score of 1.78 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.78 |
| Piotroski F-Score | 5 |